1 active not recruiting, 1 completed, 1 recruiting, 1 suspended. 4 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Suspended 1, Unknown 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Apollomics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants APL-101, PLB-1001 - Bioequivalence | Phase 1 | Unknown | Apollomics Inc. | 48 | 2022-05-20 | 2022-06-15 |
| Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) APL-101, Osimertinib - Metastatic Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 27 | 2022-01-18 | 2026-01-20 |
| Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML Uproleselan, Placebo - Relapsed/Refractory AML | Phase 3 | Terminated | Apollomics Inc. | 140 | 2021-11-17 | 2025-06-27 |
| APL-102 Capsule in Patients With Advanced Solid Tumors APL-102 Capsules - Advanced Solid Tumor | Phase 1 | Suspended | Apollomics Inc. | 30 | 2021-08-02 | 2025-06-27 |
| Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients Uproleselan - Relapsed/Refractory AML | Phase 1 | Completed | Apollomics Inc. | 12 | 2021-02-24 | 2025-06-27 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors APL-101 Oral Capsules - Solid Tumors, Advanced Cancer | Phase 2 | Recruiting | Apollomics Inc. | 497 | 2017-09-27 | 2025-06-27 |
Leukemia, Myeloid, Acute (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Glioblastoma (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Thyroid Neoplasms (1)
uproleselan (2) · Sodium Chloride (1) · osimertinib (1)
China (3) · United States (2) · Australia (1) · Canada (1) · France (1) · Hungary (1) · Italy (1) · New Zealand (1) · Russia (1) · Singapore (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Jianxiang Wang, PhD (2) · Anjali Rohatgi, M.D., Ph.D. (1) · Marietta Franco, MS (1) · Mythili Sangem (1) · Yihebali Chi, PhD (1)